|Bid||0.00 x 1300|
|Ask||0.00 x 1100|
|Day's Range||10.96 - 11.44|
|52 Week Range||8.76 - 23.10|
|Beta (3Y Monthly)||1.33|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.89|
Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 9.43% and 20.81%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $17.0 million in Q2 representing 60% growth over Q1Completed debt.
In 2007 Mike Clayman was appointed CEO of Flexion Therapeutics, Inc. (NASDAQ:FLXN). This report will, first, examine...
The Compensation Committee of the Board of Directors approved the grants with an effective date of August 1, 2019. The stock options and restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $9.77 per share and vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company.
Flexion Therapeutics, Inc. (FLXN) today announced that it will report its second-quarter 2019 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2019. Flexion Therapeutics (FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. For the past three years, Flexion has been named one of the Best Places to Work by the Boston Business Journal, and Flexion was recognized as a Top Place to Work in Massachusetts by The Boston Globe in 2017 and 2018.
Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
An analysis of clinical trial data indicates ZILRETTA reduced pain with similar improvements observed after each of two injections in patients with knee OA classified as.
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
Flexion Therapeutics, Inc. (FLXN) today announced that it has been named one of Boston Business Journal’s “Best Places to Work” for the third consecutive year. Flexion was the only Boston-area biopharmaceutical company recognized in the medium business category (100 to 249 employees). “There is tremendous competition for talent in the biotech industry, and awards like this differentiate Flexion and give us an advantage when it comes to attracting and retaining top talent,” said Michael Clayman, M.D., President and Chief Executive Officer of Flexion.
BURLINGTON, Mass., June 18, 2019 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate.
Flexion Therapeutics, Inc. (FLXN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued patent number 10,301,645 for FX201, the company's gene therapy product candidate. U.S. Patent No. 10,301,645 was awarded to Baylor College of Medicine in Houston, Texas. In December of 2017, Flexion acquired the global rights to FX201 from GeneQuine Biotherapeutics GmbH, and as part of that agreement, Flexion obtained an exclusive license to the underlying intellectual property rights from Baylor for human applications.
Flexion Therapeutics, Inc. (NASDAQ:FLXN) shareholders should be happy to see the share price up 12% in the last month...
BURLINGTON, Mass., May 14, 2019 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate.
Flexion Therapeutics, Inc. (FLXN) today announced that a pooled analysis of data from three Phase 2/3 randomized clinical trials on the use of rescue medications with ZILRETTA (triamcinolone acetonide extended-release injectable suspension) were published in Pain and Therapy. The analysis indicated that rescue medication use was significantly lower following a single injection of ZILRETTA, the first and only extended-release intra-articular therapy for OA knee pain, in comparison to placebo and TAcs.